Objective: To evaluate the clinical value of aspirin as a prophylactic for transplant renal artery stenosis (TRAS). Methods: From January 2017 to November 2019, clinical data of 307 patients who had undergone renal transplant in Zhengzhou University People's Hospital were collected. Patients were divided into two groups: the treatment group (124 recipients who had taken oral aspirin 100 mg/d after transplant) and the control group (183 recipients who had not taken aspirin after transplant). The general data, incidence of initially diagnosed and confirmed TRAS, type of renal artery anastomosis vessels, duration of stenosis, location of stenosis, and complications were compared between the two groups. The treatment group was further divided into two subgroups, the early group (92 recipients) and the delayed group (32 recipients), according to the time of starting aspirin after operation. Subgroup analysis was performed. Results: Among all 307 patients included, there were 241 males and 66 females, aged 19-64 years. There were no statistical difference between the treatment and control groups in terms of gender, age, comorbidities, number of arterial vessels, type of graft, and acute rejection all P>0.05. Among 46 initially diagnosed TRAS patients, 13 (10.5%) and 33 (18.0%) cases were in the treatment and control group respectively, with no statistically significant difference in stenosis rate (P>0.05). The number of confirmed TRAS patients was 1 (0.8%) and 24 (13.1%) in the treatment and control group respectively, with statistically significant difference in stenosis rate (P<0.001). The proportion of patients with bleeding disorders in the treatment group was slightly higher than that in the control group (13.7% vs 8.7%), and the proportion of infarct diseases was slightly lower than that in the control group (1.6% vs 4.9%). But there was no significant difference in aspirin-related complications between the two groups (P>0.05). Subgroup analysis showed that there was no significant difference in initially diagnosed and confirmed TRAS and aspirin-related complications between the early group and the delayed group (all P>0.05). Conclusions: Oral low-dose aspirin after kidney transplantation can effectively reduce the incidence of TRAS, without increasing the risk of aspirin-related complications.
目的： 探索小剂量阿司匹林预防移植肾动脉狭窄（TRAS）的有效性及安全性。 方法： 收集郑州大学人民医院2017年1月至2019年11月307例肾移植受者临床资料，根据有无口服阿司匹林分为治疗组（124例，移植后口服阿司匹林100 mg/d）和对照组（183例，移植后未服阿司匹林），对比两组患者的一般资料、初诊及确诊TRAS发生率、肾动脉吻合血管、狭窄时间、狭窄位置及并发疾病等指标；同时将治疗组根据阿司匹林应用时间不同分为早期组（92例）和延迟组（32例），并行亚组分析。 结果： 纳入的307例患者中，男241例，女66例，年龄19~64岁。治疗组和对照组患者在性别、年龄、合并疾病、动脉血管数量、移植类型及有无急性排斥反应发生方面差异均无统计学意义（均P>0.05），初诊TRAS的46例（15.0%）中，治疗组13例（10.5%），对照组33例（18.0%），两组狭窄率差异无统计学意义（P>0.05）；确诊TRAS治疗组和对照组分别有1例（0.8%）和24例（13.1%），两组狭窄率差异有统计学意义（P<0.001）；治疗组出血性疾病患者比例略高于对照组（13.7% 比 8.7%），梗死性疾病略低于对照组（1.6% 比 4.9%），但两组并发疾病方面差异均无统计学意义（均P>0.05）。对治疗组行亚组分析，发现早期组和延迟组初诊TRAS、确诊TRAS及并发疾病等方面差异均无统计学意义（均P>0.05）。 结论： 肾移植术后口服小剂量阿司匹林可有效降低TRAS发生率，且并未增加阿司匹林相关并发症的风险。.